Micromed (ARCHIMED portfolio) Acquires OSG BVBA

ARCHIMED Acquires FIM Medical

October 15, 2024

Medical Devices

ARCHIMED, a healthcare-focused private equity firm, has acquired FIM Medical, a Lyon-based leader in occupational health medical devices specializing in vision testers, audiometers and spirometers. The acquisition, executed by ARCHIMED's MED Rise fund, positions the firm to strengthen its neuro & sensory and occupational health capabilities and support FIM Medical's international expansion.

ARCHIMED Acquires 75% Stake in ActiGraph

May 18, 2020

Medical Devices

ARCHIMED (ArchiMed) has acquired a 75% stake in ActiGraph in an all-equity transaction, with management retaining 10% and other historic shareholders keeping 15%. The investment will fund ActiGraph's expansion into the regulated drug-development and clinical-trials market, accelerating product, regulatory and commercial capabilities; financial terms were not disclosed.

ARCHIMED Diagnostics Acquires 60% Stake in ARK Diagnostics

October 28, 2025

Medical Devices

ARCHIMED Diagnostics (ARCHIMED’s diagnostics team) has acquired a 60% stake in Fremont-based ARK Diagnostics from Soulbrain Holdings in a transaction valuing ARK at $428 million. Soulbrain retains and reinvests in a 40% stake and the deal includes a joint-venture agreement to accelerate ARK’s product development and global expansion.

ARCHIMED Acquires BioVendor Group

March 11, 2025

Medical Devices

ARCHIMED, a Europe-focused private equity firm specializing in healthcare, has acquired BioVendor Group, a Brno-headquartered developer and manufacturer of in‑vitro diagnostics and immunoassays. ARCHIMED will partner with existing management to accelerate internationalization, product innovation and commercial expansion as part of its MED III fund's diagnostics investment strategy.

ARCHIMED Acquires Stragen Pharma

June 24, 2021

Pharmaceuticals

ARCHIMED, through its MED Platform I fund, has acquired Stragen Pharma, a Switzerland-based developer, registrant and distributor of complex generics. The deal gives ARCHIMED majority ownership while Stragen's founder Jean‑Luc Tétard and management retain a significant minority stake; ARCHIMED plans to invest in product portfolio expansion and operational capabilities to accelerate growth in the generics market.

ARCHIMED (MED Platform II) Acquires Jeisys Medical

September 11, 2024

Medical Devices

ARCHIMED, via its MED Platform II fund, has agreed a ₩990 billion take-private acquisition of Jeisys Medical, a Seoul-based developer of energy-based aesthetic medicine devices. The transaction will delist Jeisys from the Korea Exchange and support the company’s international expansion, with founder Dong Hwan Kang reinvesting a material portion of his proceeds into the privatized business.